Cell signaling-mediated drug resistance and tumor metastasis in cancer progression.
My primary research interests are receptor tyrosine kinases (RTKs)-initiated cell signaling and epigenetic regulation of gene expression in drug resistance and tumor metastasis, with a focus on HER2-positive and triple negative breast cancer (TNBC) as well as non-small cell lung cancer (NSCLC). By understanding the molecular basis of RTK signaling in tumorigenesis and cancer progression, we hope to identify novel targets and develop effective therapeutic approaches for cancer treatment.
My primary research interests are receptor tyrosine kinases (RTKs)-initiated cell signaling and epigenetic regulation of gene expression in drug resistance and tumor metastasis, with a focus on HER2-positive and triple negative breast cancer(TNBC) as well as non-small cell lung cancer (NSCLC). By understanding the molecular basis of RTK signaling in tumorigenesis and cancer progression, we hope to identify novel targets and develop effective therapeutic approaches for cancer treatment.
Education:
MD Beijing Medical University, Beijing, China
MS Institute of Hematology,Peking Union Medical College (PUMC) & Chinese Academy of Medical Science(CAMS), Tianjin, China
Postdoctoral Training UT MD AndersonCancer Center, Houston, TX
ORCID identifier: 0000-0003-0150-8650
MyNCBI
https://scholar.google.com/citations?hl=en&user=gylZVOUAAAAJ&view_op=list_works
Selected Publications:
Lyu, H., Wang, S., Huang, J., Wang, B., He, Z., and Liu, B. Survivin-targeting miR-542-3povercomes HER3 signaling-induced chemoresistance and enhances the antitumoractivity of paclitaxel against HER2-overexpressing breast cancer. CancerLetters 420: 97-108, 2018
Lyu, H., Huang, J., He, Z., and Liu, B. Epigenetic mechanism of Survivin dysregulation in humancancer. Science China Life Sciences 61: 808-814, 2018
Wang, B., Lyu, H., Pei, S., Song, D., Ni, J., and Liu, B. Cladribine in combination withentinostat synergistically elicits anti-proliferative/anti-survival effects onmultiple myeloma cells. Cell Cycle 17: 985-996, 2018
Lyu, H., Han, A., Polsdofer, E.V., Liu, S., and Liu, B. Understanding the biology ofHER3 receptor as a therapeutic target in human cancer. Acta PharmaceuticaSinica B 8: 503-510, 2018
Lyu, H., Huang, J., He, Z., and Liu, B. Targeting of HER3 with functional cooperative miRNAsenhances therapeutic activity in HER2-overexpressing breast cancer cells.Biological Procedures Online 20: 16, 2018
Liu, X., Liu, S., Lyu, H., Riker, A.I., Zhang, Y., and Liu, B. Development of effectivetherapeutics targeting HER3 for cancer treatment. Biological Procedures Online21: 5, 2019
Luo, L., Zhang, Z., Qiu, N., Ling, L., Jia, X., Song, Y.,Li, H., Li, J., Lyu, H., Liu, H., He, Z.*, Liu,B.*, and Zheng, G*. Disruption of FOXO3a-miRNA feedback inhibition ofIGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breastcancer. Nature Communications 12: 2699, 2021 *Corresponding authors
Liu, S., Polsdofer, E.V., Zhou, L., Ruan, S., Lyu, H., Hou,D., Liu, H., Thor, A.D., He, Z., and Liu,B. Upregulation of endogenous TRAIL-elicited apoptosis is essential formetformin-mediated antitumor activity against TNBC and NSCLC. Molecular Therapy:Oncolytics 21: 303-314, 2021
Liu, H., Lyu, H., Jiang, G., Chen, D., Ruan, S., Liu, S.,Zhou, L., Yang, M., Zeng, S., He, Z., Wang, H., Li, H., Zheng, G., and Liu, B. ALKBH5-mediated m6Ademethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targetedtherapy in breast cancer. Cancer Research 2022; 82:3974-3986
Larsen, E.M., Lyu, H., and Liu, B. HER3-targeted therapeutic antibodies and antibody-drugconjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinaseinhibitors. Chinese Medical Journal - Pulmonary and Critical Care Medicine in press
(https://doi.org/10.1016/j.pccm.2022.12.001)
Topic (Keywords/Tags):
RTK, cell signaling, drug resistance, tumor metastasis, targeted therapy, epigenetic regulation, noncoding RNAs, HER2-positive breast cancer, TNBC, NSCLC
